Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.70B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.27M
Average 0.71M
Returns on capital
Zenas BioPharma, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-156.0%
avg -31.9%
ROIC
-65.6%
avg -88.5%
ROA
-98.5%
avg -88.8%
Analysis
ROIC is currently the strongest return metric at -65.6% versus its period average of -88.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Leon Oliver Moulder Jr. | Founder, CEO & Chairman | USD 891.8K | 69 | — | — |
Joseph L. Farmer | COO, President, Principal Financial Officer & Principal Accounting Officer | USD 877.5K | 54 | 175.00K | 0.39% |
Jennifer A. Fox | Chief Business Officer & Chief Financial Officer | USD 856.02K | 54 | 125.00K | 0.28% |
Lisa von Moltke | Head of Research & Development and Chief Medical Officer. | USD 759.57K | 67 | 150.00K | 0.34% |
Jerald Korn | Chief Legal and Strategy Officer | — | 47 | — | — |
Abigail Lee Gray | Director of Investor Relations | — | — | — | — |
Haley Laken | Chief Scientific Officer | — | — | — | — |
Heinrich Schlieker | Chief Technical Officer | — | — | — | — |
Jeffrey Held | Chief Legal Officer | — | 57 | — | — |
Caroline Chevalier | Chief Administrative Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jun 15, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
17
$11.42M
Sells
0
$0.00
Net Transaction Value
+$11.42M
Net buying
Most Active
MOULDER LEON O JR
9 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| May 18, 26May 18, 2026 | MOULDER LEON O JR Indirect | Buy | $1M$1,012,800.00 |
| Apr 29, 26Apr 29, 2026 | MOULDER LEON O JR Indirect | Buy | $616.7K$616,700.00 |
| Apr 28, 26Apr 28, 2026 | MOULDER LEON O JR Indirect | Buy | $450.5K$450,500.00 |
| Mar 31, 26Mar 31, 2026 | Lu Hongbo Indirect | Buy | $70.2K$70,197.84 |
| Mar 31, 26Mar 31, 2026 | Fairmount Funds Management LLC Indirect | Buy | $3M$3,000,000.00 |
| Mar 31, 26Mar 31, 2026 | MOULDER LEON O JR Indirect | Buy | $656.5K$656,540.00 |
| Mar 31, 26Mar 31, 2026 | Lu Hongbo Indirect | Buy | $1.5M$1,500,000.00 |
| Mar 30, 26Mar 30, 2026 | MOULDER LEON O JR Indirect | Buy | $364.6K$364,600.00 |
| Feb 13, 26Feb 13, 2026 | Allen Patricia L Direct | Buy | $109.7K$109,657.60 |
| Feb 12, 26Feb 12, 2026 | Allen Patricia L Direct | Buy | $132.5K$132,500.00 |
1–10 of 17
Summary
Insiders reported 17 buys worth $11.42M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $11.42M. MOULDER LEON O JR was the most active insider with 9 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +122.7% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +122.7% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Zenas BioPharma, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ZBIO's management, answered from reported figures.
Who manages ZBIO?
Zenas BioPharma, Inc. (ZBIO) lists 10 active executives. The top listed executive is Jerald Korn, Chief Legal and Strategy Officer.
Are ZBIO insiders buying or selling?
Recent insider activity shows net buying of $196.14M.
Continue the stock analysis
Jump to another research area for this company.